SEATTLE, Jan. 17, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial
media network dedicated to the North American cannabis industry, announces publication of an article discussing FSD Pharma Inc’s. (CSE: HUGE) (OTC: FSDDF) (FSE: 0K9) & Canntab Therapeutics Ltd’s. (CSE: PILL) (TBF1.F) performance in 2018.
The cannabis industry experienced significant growth last year, particularly in Canada following the legalization of adult-use
cannabis on a federal level. The upcoming legalization of edible products across Canada could open the door to further growth in
2019 and beyond. Health Canada also continues to work through its backlog of licensed producer applicants to eliminate the current
supply shortage and ensure long-term stability.
Let’s take a look at how the cannabis industry performed last year and the companies that are best positioned to profit moving
into the new year.
How Did Cannabis Stocks Perform?
The cannabis industry may be experiencing tremendous growth, but public companies have had mixed performance. According to the
Marijuana Index, Canadian cannabis companies lost about 47 percent of their value in 2018, although late-2017 and early-2018 made
for a tough comparison. Some of the ~20 index component companies also didn’t have licensed producer cultivation or sales permits
until later in the year.
The good news is that several companies experienced tremendous growth over the past year, including both well-known and
lesser-known companies. Canopy Growth Corp. registered a modest 23 percent growth rate, while Tilray Inc. posted the strongest
growth at over 340 percent. Investors may want to look between these two extremes for the best long-term opportunities.
Who Were the Best Performers?
FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) (FSE: 0K9) was the third strongest performer with
a 145.8 percent increase over the period. Based out of a former Kraft plant, the company has 25,000 sq. ft. of dedicated grow space
and $55 million in funding to expand to 220,000 sq. ft., as it looks to become the largest producer. The company began harvesting
in September 2018 and could produce upwards of 400 million grams of dried cannabis flower per year at full capacity.
In addition to its large facility, the company has investments in three companies that have or will go public, including High
Tide, Cannara Biotech, and SciCann Therapeutics. The company also has a joint venture with Auxly Cannabis Group Inc., that will
fund its Phase I buildout, and Canntab Therapeutics Ltd. (CSE: PILL) that will be manufacturing its innovative oral sustained
release tablets at the former Kraft facility.
Canntab Therapeutics Ltd. (CSE: PILL) (TBF1.F) was another top performer last year with a
50 percent increase in price. With several joint venture agreements in place, the company is preparing for the near-term
commercialization of its innovative oral sustained release cannabinoid formulations. These high profile deals include agreements
with Emblem Inc., NewCanna SAS, and Labsco Promedica to develop and distribute the products worldwide.
Unlike many other medical cannabis firms, the company has an excellent cap structure with no need for short-term financing. The
company has also applied to become a licensed producer in Canada and partnered with leading physicians to conduct clinical studies
in the pain management space. Over the long-term, the company’s goal is to become the go-to cannabinoid delivery platform for
doctors seeking more conventional products.
Looking Ahead
Canada’s cannabis industry is poised to continue seeing tremendous growth moving into 2019. With the legalization of edibles
coming in October, investors could see a significant increase in revenue and profit margins at many licensed producers. Many
licensed producers have also started to expand beyond Canada and into other global markets by leveraging the federal-level
oversight that’s uniquely available in the country.
FSD Pharma and Canntab could see continued growth moving into the new year. FSD Pharma plans to continue building out its
significant fully-funded footprint, while Canntab begins to commercialize its innovative delivery system. Both companies have
several upcoming catalysts that investors may want to keep an eye on over the coming year.
For More Information on FSD Pharma Inc. please visit the company's
website: http://fsdpharma.com/
For More Information on CannTab Therapeutics Ltd. please visit the company’s
website: https://canntab.ca/
Please follow the link to read the full article: https://www.cannabisfn.com/fsd-pharma-canntab-rank-among-the-top-2018-cannabis-stocks/
About CFN Media
CFN Media (CannabisFN) is the leading agency and financial media network dedicated to the global cannabis industry, helps
companies operating in the space attract investors, capital, and publicity. Since 2013, private and public cannabis companies in
the US and Canada have relied on CFN Media to grow and succeed.
Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/featuredcompany
Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8
Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your
iPhone: http://www.cannabisfn.com
Disclaimer
CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own
independent legal, tax, and/or investment professionals before making any investment decisions. The information provided
on http://www.cannabisfn.com (the ‘Site’) is either original financial news or paid
advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm
enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other
editorials for advertising such companies. We are not an independent news media provider. We make no warranty or
representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly
and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As
such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted.
CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along
with financial and corporate news.
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create
awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/
Frank Lane
206-369-7050
Flane@cannabisfn.com
